XNAS
BGLC
Market cap2mUSD
Oct 30, Last price
0.92USD
1D
-6.38%
1Q
-30.49%
IPO
-98.14%
Name
BioNexus Gene Lab Corp
Chart & performance
P/E
—
P/S
0.30
EPS
—
Vol. 1Y
70.15%
Shs. 5Y
16.70%
Rev. 5Y
-8.20%
Div Yld LY
—
Div Yld TTM
—
Revenues
7m
-21.93%
Net income
-3m
L+86.73%
CFO
-2m
L-17.72%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Key people
Chief Financial Officer · since 2025
Lee Su-Leng Tan
President, Chief Executive Officer, Acting Chief Financial Officer, Chief Operating Officer · since 2024
Chi Yuen Leong
Director · since 2024
Min Fong Yeat
Chairman of the Board · since 2022
Meng Wong Yee
Director · since 2024
Jook Low
Independent Director · since 2024
Teong Teoh Boon
Independent Non-Executive Director
Ping Lin Chai
Independent Non-Executive Director
Hua Yew Chak
Independent Non-Executive Director
Teng Fook Fong
Independent Non-Executive Director · since 2022
Independent Non-Executive Director · since 2022
Legal address
C/O Cloud Peak Law Group, P.C.
905 Broadway Street
Ste 100
Sheridan, WY 82801
US
905 Broadway Street
Ste 100
Sheridan, WY 82801
US
Headquarters
The Horizon, No. 8 Jalan Kerinchi
Tower 8, Avenue 5
Level 8
Bangsar South
Kuala Lumpur, 14 59200
MY
Tower 8, Avenue 5
Level 8
Bangsar South
Kuala Lumpur, 14 59200
MY
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||